Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0140 (I-vation TA) in Diabetic Macular Edema
NCT00692614Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2008
- Primary completion
- Nov 2008
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised, double-blind trial of triamcinolone acetonide in diabetic macular edema (DME) (4 arms), sponsored by Merck & Co. Primary endpoints: Change from baseline in OCT retinal thickness at 12 months and Evaluate the safety and tolerability of doses at 12 months. Started Jun 2008; status: terminated.
02
Drugs
triamcinolone acetonide
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00692614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00692614.